Henry Meds GLP-1 review: is it worth it?
Henry Meds offers compounded semaglutide and tirzepatide via subscription, including provider visits.
Cheap GLP-1 access, but real regulatory and quality caveats
Henry Meds is a legitimate US telehealth company (operating as Adonis Health Inc. since 2022) offering some of the lowest GLP-1 prices around by prescribing compounded semaglutide and tirzepatide rather than brand drugs. The active molecules are the same ones proven in major trials, and bundled pricing with no separate membership fee is genuinely attractive. The catch is that compounded GLP-1s are not FDA-approved, their legal footing narrowed sharply after the FDA declared the semaglutide and tirzepatide shortages resolved (tirzepatide in October 2024, semaglutide in February 2025), and the company has an F BBB rating tied to billing complaints plus an ongoing trademark/advertising lawsuit from Eli Lilly.
Check PriceFrom $297/mo
Pros
- ✓Among the lowest GLP-1 prices available, with injectable plans as low as roughly $197/month on annual prepay versus $1,000+ for brand drugs
- ✓All-inclusive flat pricing bundles licensed-provider telehealth visits, medication, and shipping with no separate membership fee
- ✓Offers both injectable and oral/sublingual semaglutide plus tirzepatide, giving needle-averse patients options
- ✓Real US-licensed prescribers and an established platform (operating as Adonis Health Inc. since 2022) rather than a gray-market seller, with no FDA warning letters to the company as of early 2026
- ✓Supportive medications for side effects are included in some plans, and at-home lab kit options are available
Cons
- ✕Compounded GLP-1s are not FDA-approved and skip the pre-market review, bioequivalence testing, and quality assurance of brand drugs
- ✕Legal footing narrowed sharply after the FDA declared the tirzepatide (October 2024) and semaglutide (February 2025) shortages resolved; routine 'essentially a copy' compounding is now restricted to narrow patient-specific exceptions, creating availability uncertainty
- ✕Manual vial-and-syringe dosing carries an FDA-documented risk of measurement errors compared with brand autoinjectors, with some overdoses requiring hospitalization
- ✕Documented service complaints: an F BBB rating driven by auto-renewal billing, unexpected price increases, and refund disputes, plus reports of shipping delays
- ✕Faces an ongoing Eli Lilly lawsuit (filed April 2025; a court let the 'personalized/patient-specific' advertising claim proceed in September 2025), and some compounded products industry-wide have used unapproved salt forms
How it works
Henry Meds prescribes compounded versions of GLP-1 receptor agonists, primarily semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound). These drugs mimic the gut hormone GLP-1 (tirzepatide also mimics GIP), which slows stomach emptying, signals fullness to the brain, and improves how the body regulates blood sugar and appetite. The result is reduced hunger, smaller portions, and weight loss. "Compounded" means a licensed pharmacy mixes the medication rather than it being a mass-produced, FDA-approved finished product; the FDA has warned that some compounders have used unapproved salt forms (such as semaglutide sodium or acetate) that differ from the base molecule in the approved drugs.
Active ingredient: Compounded Semaglutide / Tirzepatide
Effectiveness
Henry Meds has not published its own clinical trials; efficacy is inferred from studies of the same active molecules. In the pivotal STEP 1 trial (NEJM 2021, 1,961 adults over 68 weeks), once-weekly 2.4 mg semaglutide produced a mean 14.9% reduction in body weight versus 2.4% with placebo, and 86.4% of participants lost at least 5% of their body weight. Tirzepatide produced even larger average losses in its SURMOUNT program. Important caveat: compounded products are not FDA-approved and are not tested for the same bioequivalence, and Henry Meds' lower-strength and oral/sublingual formulations lack the trial evidence that supports the brand injectables, so individual results may differ and could be lower than the trial figures.
Side effects
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which are usually mild-to-moderate and worst during dose escalation. In STEP 1, about 4.5% of semaglutide users discontinued because of GI effects versus 0.8% on placebo. Serious but rarer risks include acute pancreatitis (severe abdominal pain), gallbladder disease, kidney injury from dehydration, and low blood sugar (especially when combined with other diabetes medications). All GLP-1 drugs in this class carry a boxed warning for thyroid C-cell tumors seen in rodents. The FDA has separately flagged compounded products for dosing errors and quality issues, including multiple adverse-event reports, some requiring hospitalization, tied to incorrect self-measured doses.
Cost
Starts at $297/mo from Henry Meds.
As of 2026, Henry Meds compounded injectable semaglutide runs roughly $297/month month-to-month, dropping to about $247/month on a 6-month plan and around $197/month on a 12-month prepay; oral and sublingual options are cheaper (often roughly $99-$249/month), and higher dose tiers typically add about $100/month (some tiers reach about $397/month). The price bundles provider visits, medication, and shipping with no separate membership fee. Compounded GLP-1s are essentially never covered by insurance and are paid out of pocket; by comparison, brand Wegovy or Zepbound can exceed $1,000/month without coverage. Note BBB complaints about auto-renewal billing, unexpected price increases, and refunds, so cancel before renewal and confirm current published pricing at signup.
Is it worth it?
If brand-name Wegovy or Zepbound is unaffordable or not covered, Henry Meds offers a markedly cheaper, real-prescriber route to the same drug classes. But you are trading FDA oversight, autoinjector convenience, and regulatory certainty for that price. Confirm current pricing and the legality of your specific prescription at signup, watch the auto-renewal billing closely, and discuss the trade-offs with your own physician before starting. This is general information, not medical advice.
Frequently asked questions
Is Henry Meds legit?
Yes. Henry Meds is a legitimate US telehealth company (operating as Adonis Health Inc. since 2022) that uses licensed prescribers and compounding pharmacies, with no FDA warning letters to the company as of early 2026. However, it has an F Better Business Bureau rating tied to billing and cancellation complaints, so read the terms carefully before signing up.
Is Henry Meds compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved. It uses the same active ingredient as FDA-approved Wegovy and Ozempic, but compounded formulations do not undergo FDA pre-market review for safety, efficacy, or quality and may differ from the brand product.
How much does Henry Meds GLP-1 cost per month?
As of 2026, compounded injectable semaglutide is roughly $297/month month-to-month, falling to about $247 on a 6-month plan and around $197 on a 12-month prepay; oral options are often cheaper. Higher dose tiers usually add about $100/month, and it is paid out of pocket since insurance rarely covers compounded drugs.
Is compounded semaglutide still legal in 2026?
Only in limited circumstances. After the FDA declared the semaglutide shortage resolved in February 2025 (and tirzepatide in October 2024), mass compounding of copies became impermissible for 503A and 503B pharmacies. Legal supply now generally hinges on narrow patient-specific exceptions, such as a documented need for a dose or form not commercially available, which makes ongoing availability uncertain.
How much weight can you lose on Henry Meds GLP-1?
Henry Meds has no published trials of its own products. In the STEP 1 trial of the same active drug, 2.4 mg semaglutide produced an average 14.9% body-weight loss over 68 weeks, with tirzepatide producing larger average losses in its trials. Real-world results vary and may be lower with compounded or lower-strength formulations.
What are the side effects of Henry Meds semaglutide?
The most common are nausea, vomiting, diarrhea, and constipation, usually worst during dose increases. Rare but serious risks include pancreatitis and gallbladder disease, and the drug class carries a boxed warning for thyroid C-cell tumors. The FDA has also warned about dosing errors specific to compounded GLP-1 products, some requiring hospitalization.
Henry Meds vs Wegovy: which is better?
Wegovy is FDA-approved, comes in a pre-filled autoinjector, and has full clinical-trial backing but costs $1,000+/month without insurance. Henry Meds is far cheaper and uses the same molecule, but it is compounded (not FDA-approved), often requires manual dosing, and faces regulatory uncertainty. Choose Wegovy if it is affordable or covered; consider Henry Meds mainly when brand access is not realistic, and discuss it with your doctor first.
Does Henry Meds take insurance?
No. Henry Meds operates on a cash-pay model, and compounded GLP-1 medications are essentially never reimbursed by insurance. The flat monthly price covers the provider visit, medication, and shipping, but you cannot bill it to insurance, and HSA/FSA eligibility is not guaranteed, so confirm with your plan administrator.
Can you cancel Henry Meds easily?
You can cancel, but a notable share of BBB complaints involve charges continuing after cancellation requests and difficulty getting refunds. Cancel before your renewal date, keep written confirmation, and review the auto-renewal and money-back-guarantee terms closely before signing up.
Sources
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine / PubMed (2021)
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration (2025)
- FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize — U.S. Food and Drug Administration (2025)
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system — Expert Opinion on Drug Safety / PubMed (2025)
- Henry Meds Semaglutide Review — Innerbody Research (2026)
- Semaglutide Side Effects: Common, Severe, Long Term — Drugs.com (2025)